Out-of-Pocket Costs for Insulin Among People with Medicare Decreased by Half Between 2020 and 2024 - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Medicare Beneficiaries’ Out-of-Pocket Insulin Costs Fell by 50% From 2020 to 2024

  • By

  • Juliette Cubanski

  • Meredith Freed

  • Anthony Damico

  • November 20, 2026

Share

Objective:

Assess changes in out-of-pocket insulin spending among Medicare Part D enrollees from 2020 through 2024 as voluntary and mandatory copay limits were introduced.

Approach:
  • Data: KFF analyzed 2020–2024 Medicare Part D prescription drug event claims from CMS’s Chronic Conditions Data Warehouse, representing 20% of Medicare beneficiaries.
  • Population: The analysis focused on Part D insulin users without Low-Income Subsidies (LIS), enrolled in stand-alone drug plans or Medicare Advantage drug plans.
Key Findings:
  • Aggregate out-of-pocket insulin spending among enrollees without LIS fell from $971 million in 2020 to $506 million in 2024.
  • Average out-of-pocket spending per insulin prescription decreased 54%, from $54 in 2020 to $25 in 2024; annual spending per insulin user fell from $572 to $265.
  • All 10 most commonly used insulin products available in both years cost more than $35 per 30-day supply in 2020; in 2024, costs for all were below $35, ranging from $23 to $29.
  • The number of insulin users without LIS rose from 1.7 million to 1.9 million, and prescriptions increased from 18.1 million to 20.4 million; prescriptions per user remained at 11 annually.
Interpretation:

The analysis reports that out-of-pocket insulin spending declined during the period when the voluntary Part D Senior Savings Model operated (2021–2023) and the Inflation Reduction Act’s mandatory $35 cap took effect in 2023. It describes these measures as associated with the decrease; the analysis does not establish that they alone caused it.

Limitations:
  • The analysis reports changes over time and does not establish that the copay limits alone caused the declines.
  • The primary analysis excludes beneficiaries receiving LIS, who pay nominal prescription copays.
Conclusion:

Among Medicare Part D insulin users without LIS, out-of-pocket spending per prescription and aggregate spending were substantially lower in 2024 than in 2020.

Sources:

Original Source(s)

Related Content